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N owadays, the treatment of tinnitus is still a great
challenge for the otolaryngologists. Many facts remain
unknown in its pathophysiology, leading to many different
therapies, with irregular results. Acamprosate is a drug used
in alcoholism treatment, due to its regulating effects in
glutamatergic and GABA neurotransmission, and has never
been used before in the treatment of tinnitus Aim: To
evaluate efficacy and safety of the acamprosate in the
treatment of sensorineural tinnitus. Study design:
randomized clinical trial. Material and Method: 50 patients
with sensorineural tinnitus were divided into two groups:
25 received acamprosate and 25 placebo, for a period of 3
months, in a prospective double-blind study, being analyzed
for its efficacy and safety by the subjective score from 1 to
10 given by the patient. Results: We found a high index of
success in the relief of tinnitus, about 86.9%. In 47.8% of
the cases we found more than 50% relief. The incidence of
side effects was low, 12%, all of them mild. Conclusion:
Acamprosate, a drug used in the treatment of alcoholism, is
a safe and successful alternative for sensorineural tinnitus’
treatment.
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INTRODUCTION
Many different types of tinnitus treatment have
recently emerged, with partially satisfactory results, reflecting
the incomplete understanding that people have about
pathophysiology 1. To many, tinnitus is a continuous problem
to Otorhinolaryngologists 2, with poor and frustrating clinical
results and dissatisfied patients. In view of this situation, any
therapeutic option that may add new possibilities of
improvement should at least be considered for our current
therapeutic arsenal.
Among the many theories already created for tinnitus
pathophysiology, one of the most widely accepted today is
the “excitotoxicity”, based on excessive release of excitatory
neurotransmitter glutamate in the peripheral and central
auditory pathways, which results in overexpression of
synaptic receptors type NMDA (N-Methyl D-Aspartate),
causing edema and rupture of primary auditory neurons,
owing to excessive input of calcium into the cells. Owing to
excessive NMDA receptors in the neurons, they get more
sensitive to excitotoxicity of the glutamate, leading to a
vicious cycle disseminated to the whole auditory pathways
(epilepsy of the auditory pathways)  1,3.
Glutamate, the main excitatory neurotransmitter
amino acid of the auditory system, both peripheral and cen-
tral, is formed from alpha-oxo-glutamate, intermediate in
Krebs cycle, by the action of GABA (Gamma-Amino-Butiric
Acid)-aminotransferase1,4.
Synaptic receptors for glutamate may be divided as
follows (Chart 1)3,5:
Chart 1. Glutamatergic receptors.
1- IONOTROPIC (open cationic channels)
1A) AMPA (Alpha Amine Methyl Propionic Acid)
1B) NMDA (N-Methyl D-Aspartate)
1C) KA (CAINATE)
2- METABOTROPIC (via by messenger)
Types 1, 2 and 3
AMPA is the English acronym for alpha-amino-3
hydroxi-5 methyl-isoxazol-propionic acid. It has fast excitatory
responses and in most physiological situations, it is relatively
impermeable to calcium 1. These are the main involved cells
with physiological synaptic transmission of auditory pathways
and it is believed that they are present in all or almost all
neurons of the central nervous system3,5.
AMPA receptors may present with a wide range of
subunits, with wide structural variations, including at the level
of post-transcriptional affections (RNA-m), which may result
in different functional properties5. In auditory pathways,
especially, there are variants of the AMPA receptors with
high permeability to calcium 3.
NMDA is an English acronym to N-methyl-D-aspartate.
It has slower excitatory responses, is highly permeable to
calcium and blocked by magnesium 1. It does not participate
in the physiological neurotransmission of auditory pathways,
and it is overexpressed in pathological conditions. However,
they seem to be involved in some neuroplasticity
mechanisms 5.
The role of kainite receptors in neurotransmission
of auditory pathways is still not very clear. In the central
nervous system, they seem to perform a secondary role
in physiological neurotransmission and in some cases,
they may also be harmful because of excessive
permeability to calcium. Some studies in rats suggested
its presence at the level of the lateral superior olivary
complex 3,5.
In metabotropic receptors, transmission of impulse is
triggered by second intracellular messengers 1.
The role of neurotransmission in auditory pathways
has still not been completely understood. Some subtypes
present regulation action of glutamatergic transmission, others
maximize it, in situations of excessive stimulus (noise, for
example)5,6.
Efferent auditory system has regulating function.
Information coming from the auditory cortex is condensed
and organized in lateral and medial olivary complexes and
then it is sent to the cochlea, through medial and lateral
olivary cochlear tracts (TOM and TOL, respectively).
TOM is responsible for efferent innervation of outer
hair cells (OHC), with fibers coming from homolateral and
contralateral medial olivary complexes. The main
neurotransmitters are acetylcholine and GABA, the latter
specially in the apical regions. TOL is responsible for efferent
innervation of inner hair cells (IHC), and it has only
homolateral fibers. The main neurotransmitters are
acetylcholine, GABA and dopamine 1,3.
Tinnitus may be classified in different ways. In our
opinion, the most appropriate way is the one that divides
them into para-auditory tinnitus (muscle and vascular) and
auditory tinnitus (generated by external, middle or inner
ears, as well as the peripheral and central pathways). The
tinnitus originated from inner ear or central and peripheral
pathway damage is named sensorineural 1,3.
Among the therapeutic possibilities for sensorineural
tinnitus, we can include drugs (such as ginkgo biloba Egb
761, clonazepam, carbamazepine, piribedil), zinc
replacement (in elderly and in cases of hypozincemia),
electro-stimulation, bio-feedback and habituation therapies
(such as T.R.T. - tinnitus retraining therapy).1,4,5According to
some authors, average efficacy of therapeutic success with
drugs ranges at about 50% 7.
The chemical name acamprosate is calcium acetyl-
homotaurinate or acetylaminopropanosulfonate whose
chemical structure is analogous to some pharmacologically
active amino acids, such as GABA, glutamate and taurine.
620
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 71 (5) PART 1 SEPTEMBER/OCTOBER 2005
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
Acamprosate acts both on the glutamatergic system
(excitatory) and in the inhibitory GABA system, counting
on the dual mechanism to treat tinnitus. No other drug used
in the treatment of tinnitus has a concomitant action in both
systems 8,9.
Acamprosate increases the number of reuptake sites
of GABA and modified GABA reuptake in rats, with global
effects of increased GABA transmission, which inhibits the
excitation of auditory pathways 8.
Acamprosate reduces the effect of excitatory amino
acids (glutamate) in the central nervous system, especially
its excitatory action over NMDA receptors, probably owing
to an action at the level of calcium channel blockers 8,9.
We intended to assess the efficacy and safety of
acamprosate in the treatment of tinnitus of sensorineural
origin by performing a double-blind randomized study.
MATERIAL AND METHOD
We selected 50 patients with tinnitus seen at OTOSUL,
Otorrinolaringologia Sul-fluminense, Hospital São Camilo, Volta
Redonda, RJ, between October 2003 and October 2004. The
inclusion criteria were tinnitus of sensorineural etiology,
excluding the cases of external and middle ear disease and
concomitant temporomandibular joint disorders. Pure tone
audiometry, vocal audiometry and immittanciometry were
performed in all patients, and we excluded those with
conductive and mixed hearing loss and those with
tympanogram curve types A-r, A-d, C and B. The audiometer
used was AMPLAID A 177 PLUS, and the Immittanciometer
was AMPLAID 750. We considered the thresholds up to 25
dB (normal hearing), 26 to 40 dB (mild loss), 41 to 70 dB
(moderate loss), 71 to 90 dB (severe loss) and over 90 dB
(profound loss).
The patients were classified according to the following
parameters:
•    age
•    gender
•    continuous or intermittent tinnitus
•    uni or bilateral tinnitus
•    tinnitus characteristics (type of associated noise)
•   time of tinnitus
•    associated symptoms (hypo and hyper loss, dizziness,
ear fullness)
•    probable tinnitus etiology
•    previous use of drugs to treat tinnitus
•    baseline tinnitus score, given by the patient, ranging from
0 to 10, according to how much it disturbed the patient
Patients were asked to score tinnitus from 1 to 10
according to how much they were disturbed by it. We allowed
0.5 scores as well.
Patients were randomly divided into 2 groups of 25
patients: one group received acamprosate 333mg, TID, and
the other received placebo, TID, both groups for 90 days.
All details of the study were clarified to the patients by the
assistant physician and they all signed the informed consent
term. It was a double-blind study approved by the Medical
Ethical Committee, Hospital São Camilo.
Patients were analyzed at days 30, 60 and 90 after
use of the drug and at each visit, the patient scored the
tinnitus status, as well as reported side effects.
The statistical analysis was performed based on the
following methods:
•    to compare quantitative data between the two groups
(acamprosate and placebo) we used t Student test for
independent samples or the Mann-Whitney test;
•    to compare qualitative data we applied the chi-square
test (χ2) or Fisher exact test;
•    to analyze the progression of tinnitus scale (quantitative
data) throughout time (four assessments within 3 months)
with the treatment with acamprosate and placebo we
performed Friedman Variance Analysis. The test of
multiple comparisons based on the statistics of Friedman
was applied to identify which moments were different.
The test of multiple comparisons is a test complementary
to Variance Analysis.
The criterion for determination of significance was
adopted as 5%, that is, when p value of the statistical test
was smaller or equal to 0.05, meaning there was statistical
significance. The statistical analysis was processed by the
statistical software SAS System.
RESULTS
The age of patients ranged from 35 to 82 years (mean
age of 60 years, median of 60.5 years). The duration of
symptoms in months ranged from 1 to 420 (mean of 101.78
months, median of 60 months).
We observed that 58% of the patients were male and
42% were female patients. The type of tinnitus most
frequently reported was wheezing sound (62% of the
patients) and whistle (46% of the patients). They also
reported sounds such as engine, pressure-cooking pain, and
cicada, and 16% of the patients had more than one type of
tinnitus concomitantly.
As to time of symptomatology (tinnitus), we observed
that 9.76% had recent tinnitus (less than 1 year), 53.65%
had intermediate tinnitus (between 1 and 7 years) and
36.59% had old cases of tinnitus (for more than 7 years).
It was observed that 58% of the patients presented
bilateral tinnitus, 72% had continuous tinnitus and 64%
reported associated symptoms. Out of the total, 59.4%
reported hearing loss, 46.9% reported dizziness, 15% had
ear fullness and 9.3% had hyperacusis. Moreover, 52% of
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the patients had already taken some type of drug to treat
tinnitus.
As to probable etiology of tinnitus, the distribution is
shown in Graph 1.
Exposure to noise as probable etiological factor
occurred in 60% of the cases. Twenty percent of the patients
presented a probable multifactorial etiology for tinnitus.
As to auditory thresholds, we observed normal
audiogram in 2 patients (4%), mild hearing loss in 30 (60%),
moderate in 10 (20%), severe in 6 (12%), and profound in 2
(4%). Out of the patients with threshold abnormalities, the
type of audiometric curve found was distributed as shown
below in Graph 2.
Considering the 50 patients, 9 interrupted treatment
before the end of assessment, 2 in the acamprosate group
and 7 in the placebo group. One patient (50%) of the
acamprosate group and 5 (71.4%) in the place group
suspended treatment owing to side effects. The other 3
patients out of 50 suspended treatment owing to family
pressure.
The proportion of improvement at day 90 (any
improvement in score, that is, the percentage of
improvement different from zero) in the group treated
with acamprosate (86.9%) was significantly greater
(p=0.004) than in the group treated with placebo
(44.4%).
The proportion of improvement at 90 days equal or
greater than 50% in the group treated with acamprosate
(47.8%) was significantly (p=0.012) higher than in the group
treated with placebo (11.1%).
In the group treated with acamprosate we did not
observe worsening in score. Three patients (13.04%) did
not report improvement, 9 (39.13%) reported improvement
below 50% and 11 patients (47.83%) reported improvement
higher than 50%. Three subjects (13.04%) reported that
tinnitus had disappeared.
To assess the progression of tinnitus score throughout
time, separately for each group, we performed Friedman
Variance Analysis. This analysis checks whether there is
Graph 1. Probable tinnitus etiology. Graph 2. Type of audiometric curve found.
Table 1. Longitudinal analysis of tinnitus scale for the group with Acamprosate (Note: SD= standard deviation; n= total number
of patients that concluded 90 days of treatment; mean, median, minimum and maximum in relation to the score.)
Tinnitus scale n Mean SD Median Minimum Maximum p value significant differences
Baseline 23 6,74 2,53 7 3 10 0,0001 Compared to 30, 60 and 90d
Score – 30d 23 5,39 2,29 5 2 10 30d, compared to 60 e 90d
Score – 60d 23 3,98 2,62 4 0 9 60d, compared to 90d 
Score – 90d 23 2,87 2,70 2 0 10
Table 2. Longitudinal analysis of tinnitus scale for the Placebo group (Note: SD= standard deviation; n= total number of patients
that concluded 90 days of treatment; mean, median, minimum and maximum in relation to the score.)
Tinnitus scale n Mean SD Median Minimum Maximum p value significant differences
Baseline 18 5,72 2,47 6 2 9 0,22 No differences
Score – 30d 18 5,51 2,33 5,5 1,5 9
Score – 60d 18 5,27 2,48 5,5 1 9
Score – 90d 18 5,17 2,77 4,5 1 10
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significant variation (fall or increase) throughout time. The
tests of multiple comparisons based on Friedman statistics
were applied to identify which times differed.
Tables 1 and 2 show mean, standard deviation (SD),
median, minimum and maximum of the scale at four
moments and the corresponding level of significance (p
value) of Friedman for the group treated with acamprosate
and placebo, respectively. The moments that differed,
identified by the test of multiple comparisons, were
highlighted in the column of significant difference, at 5%
level.
Based on Analysis of Variance, we observed that there
was significant decrease in tinnitus scale (p<0.0001) in the
group with acamprosate as a result of time. We observed in
the column of significant differences that there was significant
decrease from baseline to the other situations of assessment
(30 days) and the 3rd and 4th assessments (60 and 90 days),
as shown in Graph 3.
The Analysis of Variance showed that there was no
significant variance in tinnitus scale (p=0.22) in the group
with placebo throughout the 90 days of treatment, as shown
in Graph 3.
There was no statistically significant difference in
results of the different groups concerning age, gender,
etiology, time and type of tinnitus, level of hearing loss and
type of audiometric curve, both in the acamprosate and
placebo groups.
We observed that in the group with acamprosate there
was significant decrease in the tinnitus scale after the first
month of treatment, whereas in the placebo group there
was no significant variation during the three months.
As to side effects, analyzed by Fisher exact test, we
did not observe statistically significant difference (p=0.35)
between the groups taking acamprosate (12%) and placebo
(20%). The observed side effects with acamprosate were
mild (epigastralgia, choking), leading to interruption of
treatment in 1 case, in which the patient developed
depression, whose association with acamprosate, even
though theoretically possible, is questionable in our opinion.
DISCUSSION
Tinnitus is a very frequent symptom that affects, based
on many studies, from 14 to 32% of the general
population1,13. In 20% of the cases, tinnitus had some
repercussion in the life of the patients, which may be event
disabling in about 5% of the cases 1,13.
Treatment of tinnitus is very difficult both for the
physician and the patient, resulting in irregular outcomes,
regardless of drug or clinical approach. Some non-medication
alternatives, such as habituation (Tinnitus Retraining Therapy,
T.R.T.) may be quite effective 10,11, but the results are
perceived in the long run (18 to 24 months), requiring com-
plete integration of the patients and constant meetings with
groups of patients 23. Considering such situation, any new
perspective seems to be received as a precious new
alternative.
Studies carried out with ginkgo biloba Egb 761 extract,
at dosage of 120mg BID showed improvement of tinnitus
in 57.5% of the cases, better than the improvement obtained
with 80 mg BID (42.5%)12.
Treatment of tinnitus with carbamazepine, in
progressively increasing doses of 50 to 600 mg a day, defined
by positive lidocaine test, may result in improvement of
50% of the cases of tinnitus14.
Other drugs already studied for treatment of tinnitus
are baclofen (improvement in about 9.7%)15, caroverine
(63.3%)16, piribedil (92.6%)17, nimodipine (16.13%)18,
clonazepam (32%)19 and trimetazidine (89%)20,21. Only the
studies that investigated baclofen and caroverine were
double blind placebo-controlled studies. Trimetazidine, anti-
ischemic drug used in Europe to treat tinnitus and vertigo, is
more effective in recent tinnitus (less than 1 year of
duration)21.
In a study performed by Murai et al.22 in 1992, the
authors retrospectively assessed the use of many different
drugs in the treatment of tinnitus, including clonazepam and
flunarizine and they found rates of symptom improvement
ranging from 33 to 56%.
We did not find in the literature any reference to use
of acamprosate in the treatment of tinnitus. Its dual action
mechanism, which reduces the glutamatergic transmission
(excitatory) and increases the GABA activity (inhibitory),
together with its excellent tolerability, makes it an excellent
and promising drug for tinnitus.
Even though the subjective assessment by scores may
differ between different patients (given that tinnitus of the
same intensity may bother patients differently), we intended
to assess the therapeutic result of the medication, and
improvement in the score was the most significant factor. In
Graph 3. Tinnitus scale according to the group after 3 months of
treatment.
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our study, the percentage of tinnitus improvement was
significant (86.9%) and in 47.8% of the cases the
improvement was greater than 50%. We observed decrease
in the score given to the tinnitus in the acamprosate group
as the 90 days went by. The improvement rate was greater
than that of other drugs, and in the case of trimetazidine
(89%) and piribedil (92.6%) data were not collected from
double-blind placebo controlled studies. The study with
piribedil was carried out by general clinicians, who
concomitantly assessed other symptoms, such as vertigo and
memory deficit 17. It is important to point out that there was
no statistically significant difference in improvement
comparing factors such as age, gender, etiology, type and
duration of tinnitus, as well as severity of hearing loss and
type of audiometric curve, opening a perspective of
treatment for all cases of tinnitus of sensorineural cause.
Future studies should determine the effects of
acamprosate in relieving tinnitus for periods longer than 90
days.
CONCLUSION
In the little understood universe of tinnitus, of
multifactorial etiology and treatment with variable results,
all forms of treatment that may generate some relieve to
patients should be considered as a therapeutic option. For
this reason, acamprosate, a drug used for the treatment of
alcohol abuse, with dual action mechanism at the inner ear
and auditory pathways and excellent tolerability, should be
part of our therapeutic arsenal.
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